山东大学学报 (医学版) ›› 2019, Vol. 57 ›› Issue (10): 13-19.doi: 10.6040/j.issn.1671-7554.0.2019.639
• • 上一篇
石玉华,蒋琪
SHI Yuhua, JIANG Qi
摘要： 卵巢过度刺激综合征(OHSS)是人类辅助生殖技术中最常见、复杂的医源性并发症,其病理机制目前尚不明确,普遍认为是毛细血管壁通透性增加、体液大量外渗引起的全身血流动力学改变。OHSS发生的高危因素主要包括低龄、低体质量、高雌激素水平、多囊卵巢综合征(PCOS)、OHSS既往史等。OHSS预防在于高危人群监测及合理运用促排卵药物。对中、重度 OHSS的治疗主要是对症治疗, 以减少严重并发症的发生。
中图分类号:
| [1] Forman RG, Frydman R, Egan D, et al. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention[J]. Fertil Steril, 1990, 53(3): 502-509. [2] MacDougall MJ, Tan SL, Jacobs HS. In vitro fertilization and the ovarian hyperstimulation syndrome[J]. Human Reproduction, 1992, 7(5): 579-600. [3] Ho VNA, Braam SC, Pham TD, et al. The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count[J]. Hum Reprod, 2019, 34(6): 1055-1064. [4] Zeng C, Shang J, Jin AM, et al. The effect of luteal GnRH antagonist on moderate and severe early ovarian hyperstimulation syndrome during in vitro fertilization treatment: a prospective cohort study[J]. Arch Gynecol Obstet, 2019, 300(1): 223-233. [5] Li S, Zhou D, Yin T, et al. Dual trigger of triptorelin and HCG optimizes clinical outcome for high ovarian responder in GnRH-antagonist protocols[J]. Oncotarget, 2018, 9(4): 5337-5343. [6] Delbaere A, Smits G, De Leener A, et al. Understanding ovarian hyperstimulation syndrome[J]. Endocrine, 2005, 26(3): 285-290. [7] Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician[J]. Fertil Steril, 2010, 94(2): 389-400. [8] Zhai J, Liu J, Zhao S, et al. Kisspeptin-10 inhibits OHSS by suppressing VEGF secretion[J]. Reproduction, 2017, 154(4): 355-362. [9] Ferrero H, García-Pascual CM, Gómez R, et al. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro: implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists[J]. Fertil Steril, 2014, 101(5): 1411-1418. [10] Palumbo A, Ávila J, Naftolin F. The ovarian renin-angiotensin system(OVRAS): a major factor in ovarian function and disease[J]. Reprod Sci, 2016, 23(12): 1644-1655. [11] Herr D, Bekes I, Wulff C. Local renin-Angiotensin system in the reproductive system[J]. Front Endocrinol(Lausanne), 2013, 4: 150. doi: 10.3389/fendo.2013.00150. [12] Whelan JG 3rd, Vlahos NF. The ovarian hyperstimulation syndrome[J]. Fertil Steril, 2000, 73(5): 883-896. [13] Miller I, Chuderland D, Grossman H, et al. The dual role of PEDF in the pathogenesis of OHSS: negating both angiogenic and inflammatory pathways[J]. J Clin Endocrinol Metab, 2016, 101(12): 4699-4709. [14] 蔺莉, 魏丽惠. 吲哚美辛治疗卵巢过度刺激综合征的实验研究[J]. 中国妇产科临床杂志, 2004, 5(2): 135-137. LIN Li, WEI Lihui. The effect of indomethacin on ovarian hyperstimulation syndrome of rats[J]. Chinese Journal of Clinical Obstetrics Gynecology, 2004, 5(2): 135-137. [15] 赵菊美. 吲哚美辛治疗卵巢过度刺激综合征的疗效[J]. 浙江临床医学, 2013, 7: 1049-1050. [16] Lee TH, Liu CH, Huang CC, et al. Serum anti-Mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles[J]. Hum Reprod, 2007, 23(1): 160-167. [17] Chan WS. The ‘ART’of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology[J]. Curr Opin Obstet Gynecol, 2009, 21(3): 207-218. [18] Chan WS, Ginsberg JS. A review of upper extremity deep vein thrombosis in pregnancy: unmasking the ‘ART’ behind the clot[J]. J Thromb Haemost, 2010, 4(8): 1673-1677. [19] 赵晓鹏, 陈桂芝, 常飞, 等. 卵巢过度刺激综合征并发血栓栓塞[J]. 生殖与避孕, 2015, 35(9): 644-649. ZHAO Xiaopeng, CHEN Guizhi, CHANG Fei, et al. Ovarian hyperstimulation syndrome complicating with thrombosis[J]. Reproduction and Contraception, 2015, 35(9): 644-649. [20] Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyper stimulation syndrome: a guideline[J]. Fertil Steril, 2016, 106(7): 1634-1647. [21] Ashrafi M, Bahmanabadi A, Akhond MR, et al. Predictive factors of early moderate/severe ovarian hyperstimulation syndrome in non-polycystic ovarian syndrome patients: a statistical model[J]. Arch Gynecol Obstet, 2015, 292(5): 1145-1152. [22] Johnson MD, Williams SL, Seager CK, et al. Relationship between human chorionic gonadotropin serum levels and the risk of ovarian hyper-stimulation syndrome[J]. Gynecol Endocrinol, 2014, 30(4): 294-297. [23] Howles CM, Alam V, Tredway D, et al. Factors related to successful ovulation induction in patients with WHO group II anovulatory infertility[J]. Reprod Biomed Online, 2010, 20(2): 182-190. [24] Choux C, Barberet J, Ginod P, et al. Severe ovarian hyperstimulation syndrome modifies early maternal serum beta-human chorionic gonadotropin kinetics, but obstetrical and neonatal outcomes are not impacted[J]. Fertil Steril, 2017, 108(4): 650-658. [25] Mathur RS, Tan BK. British Fertility Society Policy and Practice Committee: Prevention of ovarian hyperstimulation syndrome[J]. Hum Fertil(Camb), 2014, 17(4): 257-268. [26] Reljic M, Vlaisavljevic V, Gavric V, et al. Number of oocytes retrieved and resulting pregnancy. Risk factors for ovarian hyperstimulation syndrome[J]. J Reprod Med, 1999, 44(8): 713-718. [27] Jayaprakasan K, Chan Y, Islam R, et al. Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1 012 women[J]. Fertil Steril, 2012, 98(3): 657-663. [28] Nargund G, Hutchison L, Scaramuzzi R, et al. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles[J]. Reprod Biomed Online, 2007, 14(6): 682-685. [29] Fischer D, Reisenbüchler C, Rösner S, et al. Avoiding OHSS: controlled ovarian low-dose stimulation in women with PCOS[J]. Geburtshilfe Frauenheilkd, 2016, 76(6): 718-726. [30] Abbara A, Islam R, Clarke SA, et al. Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment[J]. Clin Endocrinol(Oxf), 2018, 88(6): 920-927. [31] Mansour R, Aboulghar M, Serour G, et al. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome[J]. Hum Reprod, 2005, 20(11): 3167-3172. [32] DAngelo A, Amso NN, Brown J. Coasting(withholding gonadotrophins)for preventing ovarian hyperstimulation syndrome[J]. Cochrane Database Syst Rev, 2011, 66(2): CD002811. [33] 范华蕊, 张洋, 郭情情, 等. 2008~2017年体外受精/卵胞浆内单精子显微注射周期取消新鲜胚胎移植的原因构成与变化[J]. 山东大学学报(医学版), 2018, 56(9): 47-53. FAN Huarui, ZHANG Yang, GUO Qingqing, et al. Analysis on the proportion and changes of causes for cancellation of fresh embryo transfer from 2008 to 2017[J]. Journal of Shandong University(Health Sciences), 2018, 56(9): 47-53. [34] Shin JJ, Jeong Y, Nho E. Clinical outcomes of frozen embryo transfer cycles after freeze-all policy to prevent ovarian hyperstimulation syndrome[J]. Obstet Gynecol Sci, 2018, 61(4): 497-504. [35] Roque M, Haahr T, Geber S, et al. Fresh versus elective frozen embryo transfer in IVF/ICSI cycles: a systematic review and meta-analysis of reproductive outcomes[J]. Hum Reprod Update, 2019, 25(1): 2-14. [36] Zhang W, Xiao X, Zhang J, et al. Clinical outcomes of frozen embryo versus fresh embryo transfer following in vitro fertilization: a meta-analysis of randomized controlled trials[J]. Arch Gynecol Obstet, 2018, 298(2): 259-272. [37] Venetis CA, Kolibianakis EM, Toulis KA, et al. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and meta-analysis[J]. Fertil Steril, 2011, 95(1): 188-196. [38] Ben-Chetrit A, Eldar-Geva T, Gal M, et al. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial[J]. Hum Reprod, 2001, 16(9): 1880-1884. [39] Al-Inany HG. Human albumin is effective in prevention of severe OHSS[J]. Acta Obstet Gynecol Scand, 2001, 80(10): 878-882. [40] Ghahiri A, Mogharehabed N, Movahedi M, et al. Evaluation of intravenous hydroxylethyl starch, intravenous albumin 20%, and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction[J]. J Res Med Sci, 2015, 20(7): 692-696. [41] Youssef MA, Mourad S. Volume expanders for the prevention of ovarian hyperstimulation syndrome[J]. Cochrane Database Syst Rev, 2016, 8(8): CD001302. [42] Isikoglu M, Berkkanoglu M, Senturk Z, et al. Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo- controlled double blind study[J]. Fertil Steril, 2007, 88(4): 982-985. [43] Ferraretti AP, Gianaroli L, Diotallevi L, et al. Dopamine treatment for severe ovarian hyperstimulation syndrome[J]. Hum Reprod, 1992, 7(2): 180-183. [44] Basu S, Nagy JA, Pal S, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor[J]. Nat Med, 2001, 7(5): 569-574. [45] Morris RS, Paulson RJ. Increased angiotensin-converting enzyme activity in a patient with severe ovarian hyperstimulation syndrome[J]. Fertil Steril, 1999, 71(3): 562-563. [46] Leitao VM, Moroni RM, Seko LM, et al. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials[J]. Fertil Steril, 2014, 101(3): 664-675. [47] Leitao VM, Moroni RM, Seko LM, et al. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials[J]. Fertil Steril, 2014, 101(3): 664-675. [48] Lim KS, Son WY, Yoon SH, et al. IVM/F-ET in stimulated cycles for the prevention of ohss[J]. Fertil Steril, 2002, 78(3): S10-S10. [49] 杨爱军, 王钦, 牛焕付, 等. 卵母细胞体外成熟在IVF-ET周期中降低OHSS风险中的应用[J]. 生殖医学杂志, 2013, 22(11): 851-854. YANG Aijun, WANG Qin, NIU Huanfu, et al. Application of oocytes in vitro maturation for preventing ovarian hyperstimulation syndrome in IVF-ET cycles[J]. J Reprod Med, 2013, 22(11): 851-854. [50] Roque M, Lattes K, Serra S, et al. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis[J]. Fertil Steril, 2013, 99(1): 156-162. [51] Bosch E, Ezcurra D. Individualised controlled ovarian stimulation(iCOS): maximising success rates for assisted reproductive technology patients[J]. Reprod Biol Endocrinol, 2011, 9(1): 82-82. [52] 宋荣, 李寿梅, 石金月, 等. 促性腺激素释放激素拮抗剂在防治早发型中重度卵巢过度刺激综合征的应用[J]. 中华生殖与避孕杂志, 2018, 38(3): 175-180. SNOG Rong, LI Shoumei, SHI Jinyue, et al. Application of gonadotropin—releasing hormone antagonist in the prevention and treatment to fearly ovarian hyperstimulation syndrome[J]. Chinese Journal of Reproduction and Contraception, 2018, 38(3): 175-180. [53] 吕小蓉. 取卵后应用来曲唑预防卵巢过度刺激综合征(OHSS)的临床效果分析[J]. 实用妇科内分泌杂志(电子版), 2018, 5(29): 15-16,18. LV Xiaorong. The analysis of clinical effect of using letrozole to prevent OHSS[J]. Journal of Practical Gynecologic Endocrinology, 2018, 5(29): 15-16,18. [54] Tso LO, Costelo MF, Albuquerque LE, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome[J]. Cochrane Database Syst Rev, 2014, 11: CD006105. [55] Vaárnagy A, Boódis J, Maánfai Z, et al. Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome[J]. Fertil Steril, 2010, 93(7): 2281-2284. [56] Ruan X, Song J, Gu M, et al. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients[J]. Arch Gynecol Obstet, 2018, 297(6): 1557-1563. [57] Mu L, Zhao Y, Li R, et al. Metabolic characteristics of normal weight central obesity phenotype polycystic ovary syndrome women: a large-scale national epidemiological survey[J]. Reprod Biomed Online, 2018, 37(4): 498-504. |
| [1] | 郝桂敏,罗卓野,王奕卓. 生育力保存的伦理问题及思考[J]. 山东大学学报 (医学版), 2022, 60(9): 47-52. |
| [2] | 颜磊,岳彩欣,刘懿淳. 子宫内膜异位症的生育力保护[J]. 山东大学学报 (医学版), 2022, 60(9): 31-34. |
| [3] | 石玉华,潘烨,谢燕秋. 胚胎冷冻保存技术及进展[J]. 山东大学学报 (医学版), 2022, 60(9): 12-18. |
| [4] | 石玉华,王秋敏,戚丹. 辅助生殖技术前沿研究热点及进展[J]. 山东大学学报 (医学版), 2021, 59(9): 97-102. |
| [5] | 赵冰清,高选,李江夏. 基于辅助生殖人群的复发性流产夫妇染色体核型回顾性分析[J]. 山东大学学报 (医学版), 2021, 59(7): 26-31. |
| [6] | 朱序理,周亮,王跃,孙庆云,曹明雅,杜元杰,曹金凤,赵志明,郝桂敏. 不同精子来源质量冷冻方式与妊娠结局的关联性分析[J]. 山东大学学报 (医学版), 2021, 59(6): 86-93. |
| [7] | 曹明雅,赵晗洁,冯腾飞,贾蕊,赵志明,郝桂敏. 孕早期行减胎术对胚胎移植助孕患者围产期母婴的影响[J]. 山东大学学报 (医学版), 2020, 58(11): 65-70. |
| [8] | 黄薇,刘冬. 子宫内膜异位症相关不孕的助孕策略[J]. 山东大学学报 (医学版), 2019, 57(6): 23-26. |
| [9] | 师娟子,陈丽娟. 辅助生殖技术进展[J]. 山东大学学报 (医学版), 2019, 57(10): 1-6. |
| [10] | 郝桂敏,罗卓野,崔娜. 辅助生殖技术治疗中常见并发症的危害[J]. 山东大学学报 (医学版), 2019, 57(10): 7-12. |
| [11] | 范华蕊,张洋,郭情情,李福侠,唐蓉,盛燕,丁玲玲,秦莹莹. 2008~2017年体外受精/卵胞浆内单精子显微注射周期取消新鲜胚胎移植的原因构成与变化[J]. 山东大学学报 (医学版), 2018, 56(9): 47-53. |
| [12] | 卢晔,崔会芳,陈旭君,黄溢华,吴奕群,黄建隆,陈辉民,熊贤俊,陈明红. 冷冻技术在呼吸介入治疗中的应用进展及其并发症防治浅析[J]. 山东大学学报（医学版）, 2017, 55(4): 19-22. |
| [13] | 杨冬梓,麦卓瑶. 高龄多囊卵巢综合征患者的卵巢储备特点及其助孕结局[J]. 山东大学学报（医学版）, 2017, 55(1): 26-32. |
| [14] | 朱依敏. 高龄辅助生育技术子代出生缺陷及认知障碍的风险[J]. 山东大学学报（医学版）, 2017, 55(1): 11-15. |
| [15] | 邓晓惠,徐亚瑄. 高龄女性生育力评估及辅助生育[J]. 山东大学学报（医学版）, 2017, 55(1): 5-10. |
|
||
